Evidence map›Paper›PMID 20332353›Full record

Trial reportDiabetes care2010

Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes.

J Bruce Redmon, Alain G Bertoni, Stephanie Connelly, Patricia A Feeney, Stephen P Glasser, Henry Glick, Frank Greenway, Louise A Hesson, Michael S Lawlor, Maria Montez and 2 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06478173 (The Effect of Complex Exercise Training on General Health Status in Patients with Type 2 Diabetes), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06478173 nacompletednot on this mapstarted 2024, after this paper: background citation

The Effect of Complex Exercise Training on General Health Status in Patients with Type 2 Diabetes

TypeinterventionalSponsorUniversity of the Faroe IslandsRan2024 to 2024Enrolled126ConditionsType2diabetesArmsExercise training
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Cost-effectiveness of a primary care intervention to treat obesity.International journal of obesity (2005) · 2013
    Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

J Bruce RedmonDivision of Endocrinology, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA. redmo001@umn.edu
Alain G Bertoni
Stephanie Connelly
Patricia A Feeney
Stephen P Glasser
Henry Glick
Frank Greenway
Louise A Hesson
Michael S Lawlor
Maria Montez
Brenda Montgomery
Look AHEAD Research Group
Wake Forest University · USUniversity of Pennsylvania · USPennington Biomedical Research Center · USThe University of Texas Health Science Center at San Antonio · USUniversity of Alabama at Birmingham · USUniversity of Minnesota · USUniversity of Tennessee Health Science Center · USUniversity of Washington · US

Funding

Look AHEAD: Action for Health in DiabetesU01DK057136 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ESPELAND, MARK ANDREW, WAGENKNECHT, LYNNE E · 1999 to 2020
$54.9M
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI WALDERS, NATALIE · 1985 to 2008
$52.6M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HOGE, ELIZABETH A · 1985 to 2008
$37.4M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI BRYAN C BERGMAN · 1995 to 2026
$32.6M
WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI PLISZKA, STEVEN R. · 1985 to 2008
$23.1M
SHOW PROJECTU01DK057154 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1999 to 2020
$23.1M
Look AHEAD: Action for Health DiabetesU01DK057178 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1999 to 2020
$21.2M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI EARLEY, CHRISTOPHER J · 1986 to 2007
$20.2M
The Look AHEAD Continuation: Action for Health in DiabetesU01DK057078 · NIDDK · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, KAREN C · 1999 to 2020
$20.1M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW)U01DK057135 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI WADDEN, THOMAS A. · 1999 to 2020
$20.0M
The Look AHEAD Continuation: Action for Health in DiabetesU01DK056992 · NIDDK · MIRIAM HOSPITAL · PI WING, RENA R · 1999 to 2020
$20.0M
NCRR NIH HHS M01 RR000051NCRR NIH HHS M01 RR000056NCRR NIH HHS M01RR000056 44NCRR NIH HHS M01RR00051NCRR NIH HHS M01 RR001066NCRR NIH HHS M01 RR001346NCRR NIH HHS M01RR0021140NCRR NIH HHS M01 RR002719NCRR NIH HHS M01RR01066NCRR NIH HHS M01RR01346NCRR NIH HHS M01RR02719NIDDK NIH HHS DK046204NIDDK NIH HHS DK56990NIDDK NIH HHS DK56992NIDDK NIH HHS DK57002NIDDK NIH HHS DK57008NIDDK NIH HHS DK57078NIDDK NIH HHS DK57131NIDDK NIH HHS DK57135NIDDK NIH HHS DK57136NIDDK NIH HHS DK57149NIDDK NIH HHS DK57151NIDDK NIH HHS DK57154NIDDK NIH HHS DK57171NIDDK NIH HHS DK57177NIDDK NIH HHS DK57178NIDDK NIH HHS DK57182NIDDK NIH HHS DK57219NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK48520NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219
6 · The paper itself

Abstract

objectiveTo examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND

methodsLook AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy.

resultsParticipants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 +/- 1.8 for the ILI group and 3.6 +/- 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 +/- 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 +/- 1.7) at lower cost ($154/month) (P < 0.001).

conclusionsAt 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.

Indexed as

AgedAntihypertensive AgentsCardiovascular DiseasesDiabetes Mellitus, Type 2Energy IntakeExerciseFemaleHumansHypoglycemic AgentsHypolipidemic AgentsMaleMiddle AgedObesityOverweightRisk FactorsWeight LossAntihypertensive AgentsHypoglycemic AgentsHypolipidemic Agents

Identifiers

PMID20332353
PMCPMC2875414
OpenAlexW2108978856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.